How Fosamax Triggers Osteonecrosis of the Jaw: Pathophysiology and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Targeted Exposure Concerns

The legacy of general health and science communication has long emphasized broad public wellness principles, often focusing on lifestyle factors and common disease prevention. Within this framework, pharmaceutical interventions are typically presented as beneficial tools for managing chronic conditions, with their risks framed as rare or manageable through standard medical oversight. This heritage has shaped public understanding of medications like bisphosphonates, which are widely prescribed for bone density maintenance. However, as clinical experience accumulates, the focus shifts from generalized benefit-risk profiles to more specific exposure contexts. In particular, the transition from a general health audience to an occupational exposure concern requires acknowledging that certain patient populations—such as those with prolonged or high-dose medication histories—may face distinct considerations. This pivot does not entail detailing pathophysiological mechanisms, but rather recognizing that the same therapeutic agents, when examined through an occupational or exposure-focused lens, reveal patterns that warrant specialized attention. The move from a broad health narrative to a targeted inquiry into medication exposure and its potential localized effects on oral tissues represents a natural evolution in scientific discourse. This transition respects the legacy of general health education while opening a more focused dialogue on how specific pharmaceutical exposures intersect with patient vulnerability in clinical and occupational settings.

Bridging to Fosamax and Jawbone Health

Building on the recognition that certain patient populations may face distinct considerations, we now turn to Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). Understanding the pathophysiology of how Fosamax triggers ONJ requires examining the mechanistic pathways linking bisphosphonates to jawbone complications, the clinical presentation and diagnosis of ONJ, and the risk factors that contribute to its development.

Pathophysiology of Bisphosphonate-Related Osteonecrosis of the Jaw

The pathophysiology of bisphosphonate-related osteonecrosis of the jaw involves a complex interplay of drug effects on bone remodeling, vascular supply, and local immune responses. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which is their intended therapeutic mechanism for increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, this suppression of bone turnover can become excessive, particularly in the jawbone, which has a high rate of remodeling due to constant mechanical stress from chewing and the presence of teeth. The jawbone's unique structure and function make it especially vulnerable to bisphosphonate accumulation. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This research indicates that bisphosphonate treatment alters the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These changes may predispose the jawbone to necrosis when additional stressors are present.

Clinical Presentation and Diagnosis of ONJ

The clinical presentation of ONJ typically involves exposed necrotic bone in the maxillofacial region that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, with the condition often presenting after dental procedures or spontaneously. According to FDA-approved labeling, osteonecrosis of the jaw, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling further notes that known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation and Temporal Relationship

Regarding causation, the timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as symptoms appear after drug initiation, resolve upon discontinuation, and recur with rechallenge. However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be captured in clinical trials. Risk considerations for affected patients include the adequacy of warnings. The FDA-approved labeling includes a specific warning for osteonecrosis of the jaw, advising that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This suggests that warnings are present but may not fully convey the risk to all patients, particularly those with multiple risk factors. Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset, ruling out other causes such as cancer or radiotherapy, and documenting the presence of known risk factors. The timeline between exposure and harm can be variable, with symptoms appearing as early as one day or as late as several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), and the risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast-mediated bone resorption, which can lead to excessive suppression of bone turnover, particularly in the jawbone. This alters the mechanical properties of the jawbone, making it vulnerable to necrosis when additional stressors like dental procedures or infection are present (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ symptoms appear?

The time to onset of symptoms can vary from one day to several months after starting the drug. Most patients experience relief after stopping the drug, and symptoms may recur upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.